The upcoming report from Viatris (VTRS) is expected to reveal quarterly earnings of $0.52 per share, indicating a decline of 3.7% compared to the year-ago period. Analysts forecast revenues of $3.52 billion, representing a decline of 0.3% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ear ...

Group 1 - The article initiates coverage of Viatris (VTRS), a global player in the generic pharmaceutical sector, formed in 2020 through the merger of Mylan and Pfizer's Upjohn division [1] Group 2 - The company operates in developed markets and focuses on fundamental, income-oriented, long-term analysis [2] - Analysts have disclosed a beneficial long position in VTRS shares, indicating confidence in the company's performance [3]

Core Viewpoint - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising investment opportunity among cheap pharmaceutical stocks, particularly following an upgrade from UBS, which highlights the company's growth potential and efficient capital allocation [1][3]. Group 1: Company Performance and Upgrades - UBS upgraded Viatris to a Buy rating from Neutral and increased the price target from $11 to $18, reflecting stronger growth prospects [3]. - The upgrade is attributed to Viatris' new product pipeline, ongoing cost-cutting initiatives, and rising profits, which are expected to enhance shareholder value [3][10]. Group 2: Product Launches and Innovations - Viatris launched Inpefa (sotagliflozin) in the UAE, marking the first market outside the U.S. for this treatment, with plans for additional global launches [4][5]. - Inpefa is a first-in-class dual SGLT1/2 inhibitor aimed at reducing the risk of cardiovascular death and hospitalizations in patients with heart failure, including those with type 2 diabetes or chronic renal illness [5]. - The company has submitted regulatory files in Canada, Australia, and Mexico, demonstrating its capability to implement its innovative product pipeline [6]. Group 3: Strategic Focus and Future Events - Viatris is expected to prioritize the global rollout of its products leading up to a significant Investor Event on March 19, 2026, coinciding with the release of its fourth-quarter and full-year 2025 results on February 26, 2026 [6].

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [9][17][19] - Net income for the full year was $316.9 million, compared to $444.1 million in 2024, while adjusted EBITDA was $657.6 million, up from $632.2 million in 2024 [19][20] - GAAP diluted EPS was $2.50, down from $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared to $4.23 in 2024 [19][20] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10][19] - Phesgo's royalty revenue increased 51% year-over-year to $105.6 million, with total sales growing 48% to approximately $3 billion [11][19] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12][19] Market Data and Key Metrics Changes - ENHANZE-enabled products now include 10 global blockbuster opportunities, with significant approvals in multiple markets including the U.S., Japan, and China [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13][16] Company Strategy and Development Direction - The company aims to expand its ENHANZE portfolio with six new programs entering phase I in 2026, bringing the total development portfolio to 15 products [24][35] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26][27] - The company plans to pursue strategic acquisitions to enhance its drug delivery portfolio while maintaining financial discipline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers and the durability of royalty revenue [23][39] - The company anticipates continued strong growth from existing products and new launches, with a focus on expanding into new therapeutic areas [24][35] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities with long-duration IP [6][27] - The company expects to maintain a strong balance sheet and reduce net debt to below 1x by the end of 2026 [21][22] Q&A Session Summary Question: Regarding the mechanics of DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42][43] Question: On the ADC strategy and regulatory paths - Management indicated that the regulatory pathway for converting IV to subcutaneous delivery would likely follow traditional PK non-inferiority studies [49][50] Question: Update on Hypercon products and clinical testing - Management confirmed that two Hypercon products are on track for phase I clinical testing in 2026, with completion of clinical scale-up batches underway [63][64] Question: Expectations for new partnerships in auto-injectors - Management anticipates progress with high-volume auto-injectors and expects to see interest from both current and new partners [75][76]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising healthcare stock priced under $50, with a recent price target adjustment from Piper Sandler to $12 from $9 while maintaining a Neutral rating, indicating confidence in the brand's performance across various geographies and potential steady contributions from new product launches [1] Product Launch and Strategy - On January 20, Viatris announced the launch of Inpefa® (sotagliflozin) in the UAE, marking it as the first country within its territories to commercialize this treatment, with plans for future launches in several countries to enhance treatment access in key markets outside Europe and the U.S. [2] - Inpefa is the first and only dual SGLT1/2 inhibitor approved for treating heart failure, with approvals in the UAE and the U.S. to reduce hospitalization risks for heart failure and cardiovascular-related issues in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [3] Company Overview - Viatris is a global healthcare company offering a wide range of healthcare and pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare. Its operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]

Core Viewpoint - Viatris Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, with a subsequent webcast for discussion [1] Group 1: Financial Reporting - The financial results will be discussed in a webcast hosted by company executives at 8:30 a.m. ET on the reporting date [1] - Investors and the public can access the live webcast through the company's investor website or by phone [2] Group 2: Investor Events - An Investor Event is scheduled for March 19, 2026, in New York City, with more details to be provided during the February investor call [2] - Analysts and institutional investors will receive separate invitations to pre-register for the event [3] Group 3: Company Overview - Viatris is a global healthcare company that combines generics and brand medications to address healthcare needs [4] - The company aims to empower people to live healthier lives, providing access to high-quality medicines for approximately 1 billion patients annually [4] - Viatris has a diverse portfolio and a global supply chain, with headquarters in the U.S. and centers in Pittsburgh, Shanghai, and Hyderabad [4]

Core Viewpoint - Viatris Inc. announces the appointment of Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, following the transition of Brian Roman, who has served the company for over 20 years [1][2]. Group 1: Leadership Transition - Brian Roman will remain as an advisor through April 1, 2026, to ensure a smooth transition [1]. - Matthew J. Maletta brings nearly 30 years of legal experience, having previously served as Executive Vice President and Chief Legal Officer at Endo [3]. - Maletta's past experience includes over a decade at Allergan, where he was involved in significant transactions, including the $70 billion sale of Allergan to Actavis [4]. Group 2: Company Statements - Viatris CEO Scott A. Smith expressed gratitude for Brian Roman's leadership and highlighted the strength of the internal legal and compliance teams [5]. - Maletta expressed enthusiasm about joining Viatris at a pivotal time and looks forward to contributing to the company's future [5]. - Roman reflected on his experiences and accomplishments during his tenure, emphasizing the importance of the internal legal and compliance teams [5]. Group 3: Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and branded pharmaceuticals, providing access to high-quality medicines for approximately 1 billion patients annually [6]. - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India [7].

Company Overview - Viatris Inc. (VTRS) has a market capitalization of $15.1 billion and operates globally across various regions including North America, Europe, Asia-Pacific, Africa, Latin America, and the Middle East, offering a wide range of branded, generic, complex, and biosimilar medicines [1] Stock Performance - Over the past 52 weeks, VTRS shares have increased by 14.6%, slightly outperforming the S&P 500 Index, which gained 14.3% during the same period [2] - Year-to-date, VTRS stock has returned 5.1%, compared to a 1.4% rise in the S&P 500 Index [2] Financial Performance - In Q3 2025, Viatris reported an adjusted EPS of $0.67 and revenue of $3.76 billion, exceeding expectations; however, shares fell nearly 6% due to a U.S. net loss of $128 million, attributed to a reduction in the fair value of its investment in Biocon Biologics and increased income tax expenses [6] - The decline in adjusted EPS was also influenced by the negative "Indore Impact," leading to an 11% drop compared to Q3 2024 [6] Earnings Forecast - For the fiscal year ending December 2025, analysts project a 12.5% year-over-year growth in adjusted EPS to $2.32 [7] - The earnings surprise history for Viatris is mixed, with the company exceeding consensus estimates in three of the last four quarters [7] Analyst Ratings - Among 10 analysts covering VTRS, the consensus rating is a "Moderate Buy," consisting of four "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [7] - Piper Sandler recently raised Viatris' price target to $12 while maintaining a "Neutral" rating, with a mean price target of $13.33 indicating a 1.8% premium to current price levels [8] - The highest price target of $16 suggests a potential upside of 22.2% from current levels [8]

Company Overview - Viatris Inc. (VTRS) is a global pharmaceutical and healthcare company with a market cap of $14.6 billion, formed in November 2020 and headquartered in Canonsburg, Pennsylvania. The company develops, manufactures, and distributes a wide range of generic, branded, complex generic, and biosimilar medicines across more than 165 countries, serving approximately 1 billion patients annually [1]. Earnings Expectations - Analysts anticipate that VTRS will report a profit of $0.53 per share on a diluted basis for fiscal 2025 fourth-quarter earnings, reflecting a decrease of 1.9% from $0.54 per share in the same quarter last year. The company has exceeded consensus estimates in three of the last four quarters while missing on one occasion [2]. - For the full fiscal year 2025, analysts expect VTRS to report earnings per share (EPS) of $2.33, which is a decline of 12.1% from $2.65 in fiscal 2024. However, EPS is projected to increase by 6.4% year over year to $2.48 in fiscal 2026 [3]. Stock Performance - VTRS stock has increased by 15.2% over the past year, outperforming the S&P 500 Index's gain of 13.7% and the Health Care Select Sector SPDR Fund's increase of 11.1% during the same period [4]. Product Launch - On January 20, Viatris launched its heart failure treatment, Inpefa (sotagliflozin), in the United Arab Emirates, marking its first commercial launch in international markets. Inpefa is the first dual SGLT1/2 inhibitor approved for heart failure, aimed at reducing the risk of cardiovascular death and related hospitalizations, thereby enhancing Viatris' cardiovascular portfolio and innovative pipeline. Following the announcement, VTRS shares rose by 3.1% in the subsequent trading session [5]. Analyst Ratings - The consensus opinion on VTRS stock is cautious, with an overall "Moderate Buy" rating. Among ten analysts covering the stock, four recommend a "Strong Buy," five suggest a "Hold," and one advises a "Moderate Sell." VTRS is currently trading above its average analyst price target of $13 [6].

Core Insights - Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this treatment in its territories, with plans for future launches in multiple countries to expand access outside the U.S. and Europe [1][3] Product Overview - Inpefa is the first and only dual SGLT1/2 inhibitor approved for heart failure treatment, aimed at reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [2][6] - The approval of Inpefa is based on two pivotal Phase 3 trials, SOLOIST-WHF and SCORED, which enrolled over 11,800 patients globally, demonstrating significant reductions in major cardiovascular events [3][5] Clinical Efficacy - In the SOLOIST-WHF trial, Inpefa reduced the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death by 33% compared to placebo, with benefits increasing to 51% when initiated prior to discharge [3] - In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease [3] - The treatment also showed a 23% reduction in major adverse cardiovascular events (MACE), with significant reductions in myocardial infarction (32%) and stroke (34%) [3] Market Context - Heart failure is the leading cause of hospitalization globally, affecting over 64 million people, with substantial post-discharge mortality and readmission rates [4] - The 30-day post-discharge mortality rate is approximately 6.7%, with readmission rates averaging 13%, increasing to 23% mortality and 36% readmission at one year post-discharge [4] Company Strategy - Viatris aims to expand its innovative portfolio in cardiovascular diseases, leveraging its scientific leadership and commercial legacy [3][9] - The company has submitted regulatory filings for Inpefa in several countries, including Canada, Australia, and Mexico, and plans to broaden global submissions in the coming years [3][9]